[go: up one dir, main page]

KR910700076A - 가교된 항체(Cross-linked antibodies)와 그들의 제조방법 - Google Patents

가교된 항체(Cross-linked antibodies)와 그들의 제조방법

Info

Publication number
KR910700076A
KR910700076A KR1019900702232A KR900702232A KR910700076A KR 910700076 A KR910700076 A KR 910700076A KR 1019900702232 A KR1019900702232 A KR 1019900702232A KR 900702232 A KR900702232 A KR 900702232A KR 910700076 A KR910700076 A KR 910700076A
Authority
KR
South Korea
Prior art keywords
conjugate
antibody
group
bridge
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019900702232A
Other languages
English (en)
Inventor
케이스 린드 스테펀
Original Assignee
원본미기재
셀텍크 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 셀텍크 리미티드 filed Critical 원본미기재
Publication of KR910700076A publication Critical patent/KR910700076A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음.

Description

가교된 항체(Cross-linked antibodies)와 그들의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 하나이상의 비디설파이드 체인간 브리지를 가지는 표지된 항체를 포함하고, 상기 브리지는 항체의 항원 결합영역의 외측에 위치한 한개 이상의 브리징 부위에서 각 체인에 부착됨을 특징으로 하는 가교된 항체 접합체.
  2. 제1항에 있어서, 상기 브리징 부위는 아미노산 잔기의 측쇄에 존재하는 아미노기, 설피드릴기, 카르복실기, 페놀기이거나 또는 다른 방향족 혹은 헤테로 방향족 관능기임을 특징으로 하는 접합체.
  3. 제2항에 있어서, 상기 브리징 부위는 시스테인 잔기의 측쇄에 존재하는 설피디릴기임을 특징으로 하는 접합체.
  4. 제3항에 있어서, 시스테인 잔기는 힌지영역내에서 각 중쇄에 존재함을 특징으로 하는 접합체.
  5. 제4항에 있어서, 시스테인 잔기를 오직 힌지영역내에 존재하는 시스테인 잔기임을 특징으로 하는 접합체.
  6. 상기의 어느 한항에 있어서, 항체는 재조합 항체임을 특징으로 하는 접합체.
  7. 상기의 어느 한항에 있어서, 항체는 항체 단편임을 특징으로 하는 접합체.
  8. 제7항에 있어서, 단편은 F(ab′) 단편임을 특징으로 하는 접합체.
  9. 전항의 어느 한 항에 있어서, 비디설파이드 체인간 브리지는 혹은-혹은 헤테로 기능의 가교시약의 잔기임을 특징으로 하는 접합체.
  10. 전항의 어느 한 항에 있어서, 표지된 항체분자는 리포터기나 효과기가 부착된 항체분자임을 특징으로 하는 접합체.
  11. 제10항에 있어서, 리셉터기나 효과기는 NMR 혹은 ESR 스펙트로스코피, 약물학적 시약, 효소 혹은 호르몬에 의해 탐지될 수 있는 방사성 핵종, 킬레이트된 금속, 형광화합물임을 특징으로 하는 접합체.
  12. 제11항에 있어서, 리포터기나 효과기는 방사성 핵종이나 킬레이트된 금속임을 특징으로 하는 접합체.
  13. 제12항에 있어서, 방사성 핵종은 방사성 요오드임을 특징으로 하는 접합체.
  14. 제12항에 있어서, 킬레이트된 금속은 배위수 2-8개를 가진 2가 혹은 3가의 양이온 금속의 킬레이트나 폴리덴테이트 킬레이트 시약임을 특징으로 하는 접합체.
  15. 제14항에 있어서, 폴리덴테이트 킬레이트 시약은 환상 혹은 비환상의 폴리아민, 폴리에테르, 폴리아마이드, 포르피린이나 카보사이클릭 유도체임을 특징으로 하는 접합체.
  16. 제15항에 있어서, 비환상 폴리아민은 폴리아미노 카르복실산임을 특징으로 하는 접합체.
  17. 제15항에 있어서, 환상 폴리아민은 환상 트리-아자 혹은 테트라-아자 유도체임을 특징으로 하는 접합체.
  18. 한개 이상의 비디설파이드 체인간 브리지를 가지는 표지된 항체 분자를 포함하고, 상기 브리지는 한개 이상의 약학적으로 허용 가능한 담체나 부형제와 함께 항체의 항원 결합영역의 외측에 위치한 한개 이상의 브리징 부위에서 각 체인에 부착된 약학적 조성물.
  19. 한개 이상의 비디설파이드 체인간 브리지를 가지는 표지된 항체 분자를 포함하고, 상기 브리지는 항체의 항원 결합영역의 외측에 위치한 한개 이상의 브리징 부위에서 각 체인에 부착되고 항체와 반응하는 가교시약을 포함함을 특징으로 하는 항체 접합체의 제조방법.
  20. 제19항에 있어서, 항체는 가교시약보다 과잉의 농도로 존재함을 특징으로 하는 방법.
  21. 상기 표지된 항체분자는 한개 이상의 비디설파이드 체인간 브리지를 가지고 상기 브리지는 항체의 항월결합 영역의 외측에 위치한 한개 이상의 브리징 부위에서 각 체인에 부착되는 상기 항체 결합체를 사용함을 특징으로 하는 인간이나 동물을 치료나 진단하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900702232A 1989-02-10 1990-02-12 가교된 항체(Cross-linked antibodies)와 그들의 제조방법 Withdrawn KR910700076A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898903021A GB8903021D0 (en) 1989-02-10 1989-02-10 Chemical compounds
GB8903021.7 1989-02-10
PCT/GB1990/000214 WO1990009196A1 (en) 1989-02-10 1990-02-12 Cross-linked antibodies and processes for their preparation

Publications (1)

Publication Number Publication Date
KR910700076A true KR910700076A (ko) 1991-03-13

Family

ID=10651471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702232A Withdrawn KR910700076A (ko) 1989-02-10 1990-02-12 가교된 항체(Cross-linked antibodies)와 그들의 제조방법

Country Status (16)

Country Link
EP (1) EP0385601B1 (ko)
JP (1) JP2975677B2 (ko)
KR (1) KR910700076A (ko)
AT (1) ATE123653T1 (ko)
AU (1) AU636872B2 (ko)
CA (1) CA2026313A1 (ko)
DE (1) DE69020007T2 (ko)
FI (1) FI904975A7 (ko)
GB (2) GB8903021D0 (ko)
HU (1) HUT56289A (ko)
IE (1) IE67448B1 (ko)
IL (1) IL93346A0 (ko)
NO (1) NO904368L (ko)
NZ (1) NZ232489A (ko)
WO (1) WO1990009196A1 (ko)
ZA (1) ZA90982B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5922618A (en) * 1996-03-04 1999-07-13 Matsushita Electric Industrial Co., Ltd. Dye-labeled antibody conjugate and preparation method thereof
US5990286A (en) * 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
DK2900277T3 (da) 2012-12-13 2022-04-04 Immunomedics Inc Doser af immunokonjugater af antistoffer og sn-38 til forbedret effektivitet og reduceret toksicitet
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
EP3448260A4 (en) 2016-04-27 2019-10-09 Immunomedics, Inc. EFFICACY OF ANTI-TROP-2 SN-38 ANTIBODY CONJUGATES FOR THE THERAPY OF REZIDIVATED / REFRACTORY TUMORS AGAINST CHECKPOINT INHIBITORS
JP6823269B2 (ja) * 2016-06-20 2021-02-03 株式会社ＧｅｎＡｈｅａｄ Ｂｉｏ 抗体−薬物コンジュゲート
CN110392570A (zh) 2017-03-27 2019-10-29 免疫医疗公司 用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
CN111876460A (zh) * 2020-08-17 2020-11-03 郑州伊美诺生物技术有限公司 鼠单抗IgG2a F(ab`)2的制备方法
CN117466980A (zh) * 2023-11-02 2024-01-30 浙江普罗亭健康科技有限公司 基于多肽链骨架应用于金属抗体标记的负载金属缀合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751286A (en) * 1985-11-19 1988-06-14 The Johns Hopkins University Protein label and drug delivery system
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
AU636872B2 (en) 1993-05-13
NO904368D0 (no) 1990-10-09
DE69020007T2 (de) 1995-11-23
DE69020007D1 (de) 1995-07-20
NO904368L (no) 1990-12-10
GB8903021D0 (en) 1989-03-30
JPH03504645A (ja) 1991-10-09
IE67448B1 (en) 1996-04-03
IL93346A0 (en) 1990-11-29
WO1990009196A1 (en) 1990-08-23
AU5081090A (en) 1990-09-05
GB2236529B (en) 1993-03-31
HU901927D0 (en) 1991-03-28
HUT56289A (en) 1991-08-28
ZA90982B (en) 1991-10-30
EP0385601A2 (en) 1990-09-05
EP0385601B1 (en) 1995-06-14
CA2026313A1 (en) 1990-08-11
JP2975677B2 (ja) 1999-11-10
GB2236529A (en) 1991-04-10
NZ232489A (en) 1992-09-25
ATE123653T1 (de) 1995-06-15
FI904975A0 (fi) 1990-10-09
EP0385601A3 (en) 1990-11-14
FI904975A7 (fi) 1990-10-09
IE900493L (en) 1990-08-10
GB9021895D0 (en) 1990-11-21

Similar Documents

Publication Publication Date Title
KR910700076A (ko) 가교된 항체(Cross-linked antibodies)와 그들의 제조방법
KR910700075A (ko) 가교된 항체(Cross-linked antibodies)와 그들의 제조방법
Salmain et al. Labeling of proteins by organometallic complexes of rhenium (I). Synthesis and biological activity of the conjugates
KR910005862A (ko) 신규 친수성 유도체, 진단 또는 치료시 그의 응용 그를 함유하는 진단 또는 치료용 키트 및 면역 시약
KR890006584A (ko) 헤테로이작용성 커플링제
KR850002961A (ko) 메탈로티오나인 및 표적탐색용 생물학적 활성분자의 추적-표지된 접합체의 제조방법
ATE211171T1 (de) Weitgehend reine rezeptorartige, tgf-beta-1- bindende moleküle und deren verwendungen
DE69714654D1 (de) Verwendung von einem Metalloporphyrinkonjugat für den Nachweis biologischer Verbindungen
DE69519972D1 (de) Testplatte für Immunoassay
BR9707317A (pt) Processo para fazer uma composição de resina termofixa espessada
Wilbur et al. Biotin reagents for antibody pretargeting. 2. Synthesis and in vitro evaluation of biotin dimers and trimers for cross-linking of streptavidin
KR970705024A (ko) 마커그룹 및 햅텐이 선택적으로 혼입된 올리고머 담체 분자
WO1989003042A1 (en) Bidentate conjugate and method of use thereof
Ryan et al. Covalent linkage of ruthenium polypyridyl compounds to poly (L-lysine), albumins, and immunoglobulin G
AU610687B2 (en) Disulphide derivatives as linking agent
KR870005649A (ko) 고상화항체 및 그 제조방법
Schott et al. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments
Salmain et al. [. eta. 5-Cyclopentadienyl] metal Tricarbonyl Pyrylium Salts: Novel Reagents for the Specific Conjugation of Proteins with Transition Organometallic Labels
DE60137186D1 (de) Trizyklische Antidepressiva und Immunoassay
FI104409B (fi) Kelaatinmuodostajia ja niitä sisältäviä, diagnostiikassa käytettäviä komplekseja
JPH02263161A (ja) 堅牢なカップリング化合物の中間体
Wilbur et al. Monoclonal antibody Fab'fragment crosslinking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F (ab') 2 fragments
FR2644167B1 (fr) Procede de condensation d'au moins un epoxyde sur au moins un anhydride cyclique en presence d'un catalyseur a base d'au moins un complexe de titane
Baut et al. Preparation of isodesmosine‐KLH conjugate for ELISA system
Lux et al. Reappraisal of the binding processes of N-(3-pyrene) maleimide as a fluorescent probe of proteins.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19901010

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid